Loading
This study tests TROP-2-directed treatment; the registry reports that it is terminated.
The registry lists NCT04601285 as terminated, last updated 2023-07-06. Enrolment is 25 actual participants. Interventions: JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection). Primary measures include First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD); Number of participants with adverse events (AEs). The registry reason for stopping is: Sponsor has adjusted study development plan and terminated this clinical study. No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-08. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/